Author

A. Shinde

Observed names: A Shinde, Akshada Shinde

Institutions: Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals, Suven Life Sciences (India)

Observed institutions: Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals, Suven Life Sciences (India)

ORCID: 0009-0001-0999-7287

Observed ORCID: 0009-0001-0999-7287

OpenAlex ID: A5023539276

Therapeutic Potential of 5-HT6 Antagonist SB399885 in Traumatic Stress Disorder

2014 · R. Abraham, R. Nirogi, et al. · Drug Research · 7

A Cross Sectional Study on Awareness of Animal Bite Management and Rabies Immunization Among General Practitioners in a Metropolitan City of India

2022 · Monali Kadam, Akshada Shinde · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · 1

0155 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Differentiating Features Over Current Treatments of Narcolepsy

2020 · A Shinde, R Subramanian, et al. · SLEEP · 1

Samelisant (SUVN-G3031): A Phase-2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Narcolepsy with and without Cataplexy

2022 · V.K. Goyal, R. Nirogi, et al. · Sleep Medicine

Beneficiaries' Perspective in Reducing Child Deaths Due to Malnutrition in Tribal District of Maharashtra: a Qualitative Study

2021 · Lalit Sankhe, Chhaya Rajguru, et al. · GLOBAL JOURNAL FOR RESEARCH ANALYSIS

0759 Phase 2 Proof Of Concept Study Of SUVN-G3031, A Histamine H3 Receptor Inverse Agonist For The Potential Treatment Of Narcolepsy

2020 · R Nirogi, V Goyal, et al. · SLEEP

0008 SUVN-G3031, A Histamine H3 Receptor Inverse Agonist Produces Robust Wake Promoting and Anticataplectic Activity in Orexin Knockout Mice

2020 · V Benade, S Daripelli, et al. · SLEEP

SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of narcolepsy with or without cataplexy – Differentiating factors with competitor clinical candidates

2019 · R. Nirogi, G. Bhyrapuneni, et al. · Sleep Medicine

Safety, tolerability and pharmacokinetics of a potent and selective histamine h3 receptor inverse agonist, SUVN-G3031 following single and multiple ascending doses in healthy subjects

2019 · R. Nirogi, K. Mudigonda, et al. · Sleep Medicine

P316 Estimation de la réduction du risque cardiovasculaire dans un sous-groupe de patients de l’étude A1chieve en utilisant l’algorithme UKPDS

2014 · J. Courrèges, A. Al Gunaid, et al. · Diabetes & Metabolism

Works count: 10

Citation count: 9

H-index: 1

I10-index: